GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034.
GLP-1 agonists, known to be beneficial in treating type 2 diabetes, are glucagon-like peptide-1 receptor agonists. The action of GLP-1 RAs is to enhance insulin synthesis and inhibit glucagon secretion by activating GLP-1 receptors. While all GLP-1 RAs have the exact mechanism of action, there are differences in formulation, dose, injection technique, and administration.
The considerable cardiovascular benefits associated with specific GLP-1 agonists and the well-documented efficacy of GLP-1 agonists in diabetes care are two key drivers driving this industry ahead. These drugs help manage type 2 diabetes by increasing insulin production and decreasing glucagon release, improving blood sugar control and cardiovascular health. GLP-1 agonists have demonstrated potential in managing weight, a crucial motivation. Because type 2 diabetes and obesity are frequently co-occurring, this technique is very helpful in managing both conditions. Because these drugs lead to weight loss, they appeal to patients and doctors. Furthermore, developing new treatments is anticipated to fuel the growth of the GLP-1 receptor agonist market.
However, the market development is hampered by the high-cost criteria for the safety and health of the GLP-1 agonists market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high GLP-1 agonists because GLP-1 agonists are expensive, which can prevent some patients from getting the treatment they need. There may not be extensive use due to this financial obstacle and worries about injections. There may not be extensive use due to this financial obstacle and worries about injections. One potential future hurdle for the growth of the market for glucagon-like peptide 1 (GLP-1) agonists is the availability of suitable insurance. As a result of COVID-19-related travel restrictions and lockdowns, the worldwide supply chain for GLP-1 receptor agonists was disrupted. Because of this, the healthcare business was hit hard by the COVID-19 pandemic, which disrupted the supply chain and compromised processes ranging from ingredient procurement to final delivery.
o Novo Nordisk A/S
o Eli Lilly and Company
o Sanofi S.A.
o Biocon Limited
o Boehringer Ingelheim International GmbH
o Amgen Inc.
o AstraZeneca PLC
o Roche Holding AG
o Zealand Pharma A/S
o Hanmi Pharmaceutical Co., Ltd.
o Structure Therapeutics Inc.
o Altimmune, Inc.
o United Laboratories International Holdings Limited
o Entera Bio Ltd.
o OPKO Health, Inc.
o Viking Therapeutics, Inc.
o Twist Bioscience Corporation
The GLP-1 agonists market is segmented based on product, application, route of administration and distribution channel. As per the Product, the market includes Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound, Other Products. Whereas, by Application, the market is divided into Type 2 Diabetes Mellitus, and Obesity. Acccording to the Route of Administration, the market is segmented into Parenteral, and Oral. Distribution channel includes hospital pharmacies, retail pharmacies, and online pharmacies.
Retail pharmacies make up the bulk of GLP-1 agonists usage because participating in retail pharmacies in clinical trials provides more individualized patient care. As the initial point of contact for many patients seeking medical assistance, retail pharmacists can be crucial in identifying individuals suited for clinical trials, particularly in nations like the US, Germany, the UK, China, and India.
The North American GLP-1 agonists market is expected to register the highest market share in revenue in the near future. The area has a well-developed healthcare infrastructure, major actors are present, the disease prevalence is high, and investments in research and development for novel medications to treat diabetes and obesity are expanding. In addition, Asia Pacific is projected to increase in the global GLP-1 agonists market because diabetes and other linked illnesses are becoming more common. With more generic pharmaceuticals hitting the market, the glucagon-like peptide 1 (GLP-1) agonists market is expected to develop in the region.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 43.1 Bn |
| Revenue Forecast In 2034 | USD 260.1 Bn |
| Growth Rate CAGR | CAGR of 19.9% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product, Indication , Route of Administration, Distribution Channel and Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; Japan; South Korea; Southeast Asia |
| Competitive Landscape | Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Biocon Limited, Boehringer Ingelheim International GmbH, Amgen Inc., AstraZeneca PLC, Roche Holding AG, Zealand Pharma A/S, Hanmi Pharmaceutical Co., Ltd., Structure Therapeutics Inc., Altimmune, Inc., United Laboratories International Holdings Limited, Entera Bio Ltd., OPKO Health, Inc., Viking Therapeutics, Inc., Twist Bioscience Corporation and others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
GLP-1 Receptor Agonist By Product-
· Branded GLP-1 Agonists
o Semaglutide-based
§ Ozempic (injectable)
§ Rybelsus (oral)
§ Wegovy (obesity)
o Liraglutide-based
§ Victoza
§ Saxenda
o Dulaglutide-based
§ Trulicity
o Exenatide-based
§ Byetta
§ Bydureon
o Lixisenatide-based
§ Lyxumia / Adlyxin
· Dual / Triple Agonists
o GLP-1 + GIP Agonists
o GLP-1 + Glucagon Agonists
o Triple Agonists (GLP-1 + GIP + Glucagon)
· Biosimilars & Generic GLP-1 Agonists
GLP-1 Receptor Agonist By Indication-
GLP-1 Receptor Agonist by Route of Administration
GLP-1 Receptor Agonist by Distribution Channel
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.